What volume of a 10 MG/ML retatrutide solution corresponds to a 1 MG dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Retatrutide Reconstitution Calculation

You need to draw 0.1 mL (or 10 units on a standard insulin syringe) to obtain a 1 mg dose of retatrutide.

Calculation Breakdown

When you reconstitute 10 mg of retatrutide powder with 1 mL of bacteriostatic water, you create a solution with a concentration of 10 mg/mL.

To determine the volume needed for a 1 mg dose:

  • Desired dose: 1 mg
  • Concentration: 10 mg/mL
  • Volume = Dose ÷ Concentration
  • Volume = 1 mg ÷ 10 mg/mL = 0.1 mL

Syringe Measurement Conversion

  • 0.1 mL equals 10 units on a standard U-100 insulin syringe (where 100 units = 1 mL) 1
  • This is the same volume relationship used in medication dosing calculations, where converting mg/kg dosage to mL/kg follows the principle that concentration determines volume 1

Important Safety Considerations

Verify your concentration before every injection. The concentration changes dramatically based on the volume of diluent you add:

  • 1 mL bacteriostatic water = 10 mg/mL concentration (as in your case)
  • 2 mL bacteriostatic water = 5 mg/mL concentration
  • Different volumes require different syringe measurements for the same dose 1

Use proper injection technique. Retatrutide is administered subcutaneously, similar to other peptide medications 2, 3. The medication should be injected slowly to minimize local reactions.

Monitor for adverse effects. The most common side effects are gastrointestinal (nausea, diarrhea, vomiting), which are dose-related and typically mild to moderate 2, 3. Retatrutide can also cause dose-dependent increases in heart rate that peak around 24 weeks 2.

Clinical Context

Retatrutide is a triple-hormone receptor agonist (GIP, GLP-1, and glucagon receptors) being developed for obesity and type 2 diabetes 4, 2. In clinical trials, doses ranging from 1 mg to 12 mg weekly have been studied, with higher doses producing greater weight loss but also more gastrointestinal side effects 2, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.